Kineta, Inc. , a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners.
Kineta stock last closed at $0.62, down 7.46% from the previous day, and has decreased 84.46% in one year. It has underperformed other stocks in the Biotechnology industry by 0.61 percentage points. Kineta stock is currently +85.63% from its 52-week low of $0.33, and -88.5% from its 52-week high of $5.39.
As of Apr 24, 2024, there are 10.96M shares of KA outstanding. The market value of KA is $6.80M. In the last 24 hours, 172,143 KA shares were traded.
You need a brokerage account to access the NASDAQ market and buy KA shares.
Based on our research, eToro is the best online stock brokerage. Here's why:
Get $10 towards your stock purchase by opening an account with eToro today.
Open eToro AccountNow that you've picked your brokerage, you need to fill out some personal information so you are able to invest in KA today.
Now that you have opened your account on the best app for stock investing, you can securely and quickly fund your account:
Check out this video walkthrough to see the process of transferring funds into your brokerage account.
Once you have selected the best place to buy Kineta stock, it's crucial to evaluate their stock prior to buying, so you truly understand the risk as well as the upside.
WallStreetZen was designed to help everyday investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on KA's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge KA's true value.
Using relative valuations methods:
You can do additional valuation research on KA's stock here.
Out of 1 sell side analysts who give recommendations on KA, the consensus analyst rating on KA is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Kineta stock forecast page.
Last year, KA revenue was $5.44M. In the last five year, KA's revenue has grown by 13.89% per year. This was slower than the Biotechnology industry average of 28.91%.
Dive into KA's earnings and revenue performance here.
In the last year, insiders at KA have bought more shares than they have sold.
Raymond J. Bartoszek, Director of KA, was the latest KA insider to buy. They bought $1,125.00 worth of KA stock on Dec 6, 2023.
Get more info about who owns KA shares here.
No, Kineta doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
There are two main options:
Click the Open Trade button and your broker will execute the order.
If you need additional help with investing in stocks on eToro, watch the helpful video below:
Now that you own some shares in KA, you'll want to keep up with your new investment.
Start a watchlist to track your KA stock.
To summarize, here are the 6 steps to buy Kineta stock:
If you require a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get notifications regarding your new investment in Kineta, get started below.